Prospect: information for the user
Venlafaxine Retard Qualigen 150 mg prolonged-release hard capsulesEFG
Venlafaxina Retard Qualigen contains the active ingredient venlafaxine.
Venlafaxina Retard Qualigen is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders. The exact way in which antidepressants work is not fully understood, but they may help to increase the levels of serotonin and noradrenaline in the brain.
Venlafaxina Retard Qualigen is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: social anxiety disorder (fear or avoidance of social situations), generalized anxiety disorder and panic disorder (panic attacks). Treating depressive and anxiety disorders properly is important to help you feel better. If left untreated, your condition may not go away or may worsen and become harder to treat.
Consult your doctor or pharmacistbeforestarting to take Venlafaxina Retard Qualigen:
Venlafaxina Retard Qualigen may cause a feeling of restlessness or difficulty sitting or staying still during the first weeks of treatment. You should consult your doctor if this occurs.
If you are depressed and/or have an anxiety disorder, you may sometimes have thoughts of harming yourself or committing suicide. These thoughts may increase when starting to take antidepressants, as all these medications take time to become effective, usually two weeks but sometimes longer.These thoughts may also occur when your dose decreases or during the interruption of treatment with venlafaxine.
It is more likely to happen:
If you have thoughts of harming yourself or committing suicide at any time, contact your doctor or go to the hospital directly.
You may find it helpful to tell a close family member or friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You can also ask them to tell you if they think your depression or anxiety is worsening, or if they are concerned about changes in your behavior.
Dry mouth
Dry mouth has been reported in 10% of patients treated with venlafaxine. This may increase the risk of dental deterioration (caries). Therefore, you should take care of your dental hygiene.
Diabetes
Your blood glucose levels may be altered due to Venlafaxina Retard Qualigen. Therefore, you may need to adjust the dose of your diabetes medication.
Some medications in the group to which Venlafaxina Retard Qualigen belongs (called IRSN) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms persist after stopping treatment.
Venlafaxina Retard Qualigen should not be used normally in the treatment ofchildren and adolescents under 18 years old. Additionally, you should know that in patients under 18 years oldthere is agreater risk of adverse effects such as attempts at suicide,suicidal thoughtsand hostility (predominantly aggression, confrontational behavior and irritability) when taking this type of medication. However, the doctor who prescribes this medication to you may prescribe it to patients under 18 years old when they decide what is best for the patient. If yourdoctorhas prescribed this medication to a patient under 18 years old and you want to discuss this decision,please go backto your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen in these patients under 18 years old who are taking Venlafaxina Retard Qualigen. Additionally, the long-term safety in relation to growth, maturation and cognitive and behavioral development of this medication in this age group has not been demonstrated.
Inform your doctor or pharmacist if you are using, have used recently or may need to use other medications.
Your doctor must decide if you can take Venlafaxina Retard Qualigen with other medications.
Do not start or stop taking any medication, including those sold without a prescription, natural remedies and herbal remedies, before checking with your doctor or pharmacist.
A potentially fatal state, or reactions similar to Malignant Neuroleptic Syndrome (MNS) (see section “Possible Side Effects”), may occur with treatment with venlafaxine, particularly when taken with other medications.
Examples of these medications include:
The signs and symptoms of serotonin syndrome may include a combination of the following:
restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, vomiting.
In its most severe form, serotonin syndrome may resemble malignant neuroleptic syndrome (MNS). The signs and symptoms of MNS may include a combination of fever, rapid heartbeat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).
Inform your doctor immediately or go to the nearest hospital emergency room if you think you are experiencing serotonin syndrome.
Inform your doctor if you are taking medications that may alter your heart rhythm.
Some examples of these medications include:
The following medications may also interact with Venlafaxina Retard Qualigen and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medications that contain:
Venlafaxina Retard Qualigen should be taken with food (see section 3 “HOW TO TAKE VENLAFAXINA RETARD QUALIGEN”).
Do not drink alcohol while taking Venlafaxina Retard Qualigen. The concomitant use with alcohol may cause extreme fatigue and unconsciousness and may worsen your depression symptoms and other conditions, such as anxiety disorders.
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
You should only take Venlafaxina Retard Qualigen after discussing with your doctor the possible benefits and risks for the unborn baby.
Make sure your midwife and/or doctor know that you are taking Venlafaxina Retard Qualigen. When taken during pregnancy, similar medications (ISRS) may increase the risk of a serious condition in newborns, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear blue. These symptoms usually appear within the first 24 hours after the baby's birth. If this happens to your baby, you should contact your midwife and/or doctor immediately.
If you are taking this medication during pregnancy, in addition to breathing problems, another symptom your baby may have when born is feeding problems. If your baby has these symptoms when born and you are concerned, contact your doctor and/or midwife who can advise you.
If you take Venlafaxina Retard Qualigen in the final stages of pregnancy, there may be a greater risk of heavy vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know that you are taking Venlafaxina Retard Qualigen to be able to advise you.
Venlafaxina Retard Qualigen passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the case with your doctor and they will decide if you should stop breastfeeding or stop taking this medication.
Driving and operating machines
Do not drive or operate tools or machines until you know how this medication affects you.
Venlafaxina Retardcontains sodium
This medication contains less than 1 mmol of sodium (23 mg) per capsule; this is, essentially “sodium-free”.
The usual recommended initial dose for the treatment of depression, generalized anxiety disorder, and social anxiety disorder is 75 mg per day. Your doctor may gradually increase the dose and if necessary, further increase it up to a maximum of 375 mg per day for depression. If you are being treated for panic disorder, your doctor will start with a lower dose (37.5 mg) and then gradually increase the dose. The maximum dose for generalized anxiety disorder, social anxiety disorder, and panic disorder is 225 mg/day.
Take Venlafaxina Retard Qualigen approximately at the same time every day, either in the morning or at night. The capsules should be swallowed whole with liquids and should not be opened, crushed, chewed, or dissolved.
Venlafaxina Retard Qualigen should be taken with food.
If you have liver or kidney problems, talk to your doctor as your dose of this medication may need to be different.
Do not stop taking this medication without consulting your doctor (see section “If you interrupt treatment with Venlafaxina Retard Qualigen”).
Call your doctor or pharmacist immediately if you take more of this medication than prescribed by your doctor. You can also contact the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
The symptoms of a possible overdose may include palpitations, changes in alertness (ranging from drowsiness to coma), blurred vision, seizures or attacks, and vomiting.
If you have missed a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose as usual. Do not take a double dose to compensate for the missed doses. Do not take more than the daily dose of Venlafaxina Retard Qualigen prescribed to you in a day.
Do not stop taking your treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor thinks you no longer need Venlafaxina Retard Qualigen, they may ask you to gradually reduce the dose before stopping treatment completely. It is known that adverse effects occur when people stop using this medication, especially when it is stopped suddenly or if the dose is reduced very quickly. Some patients may experience symptoms such as suicidal thoughts, aggression, fatigue, dizziness, instability, headaches, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, confusion, tinnitus, tingling, or in rare cases, electric shock sensations, weakness, sweating, seizures, or flu-like symptoms, vision problems, and increased blood pressure (which can cause headaches, dizziness, tinnitus, sweating, etc.).
Your doctor will advise you on how to gradually stop treatment with Venlafaxina Retard Qualigen.This may take several weeks or months. In some patients, the interruption may need to be produced very gradually over months or more.If you experience any of these or other symptoms that bother you, consult your doctor for further advice.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If any of the following effects occur, do not take more Venlafaxina Retard Qualigen.Inform your doctor immediately, or go to the nearest hospital emergency room:
Rare (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
In its most severe form, serotonin syndrome may resemble neuroleptic malignant syndrome (NMS). NMS symptoms and signs may include a combination of fever, rapid heart rate, severe muscle rigidity, confusion, increased muscle enzymes (determined by blood tests).
Unknown frequency (cannot be estimated from available data)
Other side effects that you should inform your doctor are (the frequency of these side effects are included in the list below "other side effects that may occur"):
Other side effects that may occur
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data)
Venlafaxina Retard Qualigen may sometimes cause unwanted effects that you may not be aware of, such as increased blood pressure or abnormal heart rhythm; mild changes in liver enzyme levels, sodium, or cholesterol levels. Your doctor may wish to perform occasional blood tests, particularly if you have been taking Venlafaxina Retard Qualigen for a long time.
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:http://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not usethis medication after the expiration date that appears on the box and the blister pack, after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above30°C.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at thePharmacy Take-Backpoint. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
The active ingredient is venlafaxine.
Each prolonged-release capsule contains 150 mg of venlafaxine as venlafaxine hydrochloride.
The other components are:
Capule content:hypromellose, ammonio methacrylate copolymer (type B), sodium lauryl sulfate (E487), magnesium stearate.
Coating:butylated basic methacrylate copolymer 12.5%,
Capsule:gelatin, titanium dioxide (E171), erythrosine (E 127), indigotin I (E 132)
Printing ink:Shellac, iron oxide black (E172), propylene glycol (E1520).
Venlafaxina Retard Qualigen 150 mg hard capsules with prolonged release: hard gelatin capsules of opaque red color (size 00) containing three coated, round, and biconvex tablets, printed with VEN on the cap and 150 on the body.
Packagings containing 28, 30, or 98 capsules.
Only some packaging sizes may be marketed.
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Responsible for manufacturing
Pharmathen, S.A.
6, Dervenakion Str. – GR – 15351
(Pallini. Attikis) Greece
Or
Pharmathen International S.A.
Sapes Industrial Park
Block 5, 69300 Rodopi
Greece
Or
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Last review date of this leaflet:June 2024
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.